^
    4ms
    A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions (clinicaltrials.gov)
    P1, N=11, Terminated, Apros Therapeutics, Inc | Completed --> Terminated; Study terminated prematurely due to internal corporate decision
    Trial termination
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    APR003
    almost3years
    A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions (clinicaltrials.gov)
    P1, N=11, Completed, Apros Therapeutics, Inc | Recruiting --> Completed | N=36 --> 11 | Trial completion date: Dec 2023 --> Jan 2023 | Trial primary completion date: Oct 2023 --> Jan 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    APR003
    almost5years
    A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions (clinicaltrials.gov)
    P1, N=36, Recruiting, Apros Therapeutics, Inc | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    APR003
    5years
    A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Apros Therapeutics, Inc
    Clinical • New P1 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    APR003